ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

CHANGE IN CONTROL

On December 9, 2021, Integra LifeSciences Holdings Corporation (the "Company") adopted a change in control severance program (the "Program") under which certain executives of the Company, including Carrie Anderson, Executive Vice President and Chief Financial Officer, Glenn G. Coleman, Executive Vice President and Chief Operating Officer, Robert T. Davis, Jr., Executive Vice President, President - Tissue Technologies, and Michael McBreen, Executive Vice President, President - Codman Specialty Surgical, are participants (each, an "executive participant"). The Program is effective as of January 1, 2022, and renews the Program for executive participants scheduled to expire on December 31, 2021.



The Program provides for the payment of severance and other benefits to the
executive participants in the event of a "qualifying termination," which means a
termination of employment with the Company without "cause" or by the executive
participant for "good reason," in either case, on or within two years following
a "change in control" of the Company and so long as such change in control
occurs by December 31, 2022 (each, as defined in the Program). In the event of a
qualifying termination, the Program provides for:
•         a lump sum payment equal to 1.5 times (or 2 times for Ms. Anderson and Mr. Coleman)
          the sum of the executive participant's annual base salary and target cash bonus;

•         a lump sum payment equal to a pro rata portion of the executive participant's target
          cash bonus for the partial fiscal year in which the termination occurs;

•         Company-subsidized COBRA premium payments for up to eighteen months following the
          termination date;

•         Company-paid outplacement services for up to twelve months following the termination
          date; and

•         to the extent the executive participant has not yet received his or her short-term
          annual cash bonus for prior-year performance with the Company, the executive
          participant shall still receive such short term annual cash bonus for prior-year
          performance at the time non-terminated employees receive such short term annual cash
          bonus if such payment is due.

An executive participant's right to receive the severance payments and benefits described above is subject to the delivery and non-revocation of an effective general release of claims in favor of the Company.

In addition, under the Program, to the extent that any change in control payment or benefit would be subject to an excise tax imposed in connection with Section 4999 of the Internal Revenue Code, such payments and/or benefits may be subject to a "best pay cap" reduction to the extent necessary so that the executive participant receives the greater of the (i) net amount of the change in control payments and benefits reduced such that such payments and benefits will not be subject to the excise tax and (ii) net amount of the change in control payments and benefits without such reduction.

The term of the Program expires on December 31, 2022, and any extension of the term requires the approval of the Compensation Committee of the Company's Board of Directors. However, upon the occurrence of a change in control, the term will automatically be extended until the two-year anniversary of the date on which the change in control occurs. In addition, if an executive participant incurs a qualifying termination during the term of the Program, the term automatically will be further extended until each party's rights and obligations are fully satisfied.

The foregoing description of the Program is not complete and is subject to and qualified in its entirety by the terms of the Program, a copy of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

10.1 Change in Control Severance Program

--------------------------------------------------------------------------------

104 Cover Page Interactive Data File (embedded within the inline XRBL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses